Emcure Pharmaceuticals (NSE:EMCURE) Current Deferred Revenue: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,927.60
! 4 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Current Deferred Revenue?

Emcure Pharmaceuticals NSE:EMCURE +3.93% 41 Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Emcure Pharmaceuticals's current deferred revenue for the quarter that ended in Jun. 2026 was ₹0 Mil.

Emcure Pharmaceuticals Current Deferred Revenue Related Terms

Emcure Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Current Deferred Revenue Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Current Deferred Revenue of ₹0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Emcure Pharmaceuticals and its competitors.
Is Emcure Pharmaceuticals' Current Deferred Revenue too high?
Emcure Pharmaceuticals' current Current Deferred Revenue is ₹0 Mil. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Current Deferred Revenue compare to ZTS?
Emcure Pharmaceuticals' Current Deferred Revenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Current Deferred Revenue of ₹0 Mil. The current Current Deferred Revenue is ₹0 Mil. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,927.60
Price